Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
Santen Pharmaceutical has highlighted its investigational pterygium therapy STN10142 as a promising pipeline candidate, targeting a potential patient population of around 4 million in Japan. At an online R&D briefing on March 19, the ophthalmology specialist framed the drug —…
To read the full story
Related Article
- Santen, RemeGen Win China Filing Acceptance for RC28-E in DME
October 1, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…